Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and Response System
World Health Organization
ጁን 2025 · World Health Organization
ኢ-መጽሐፍ
35
ገጾች
family_home
ብቁ
info
reportየተሰጡት ደረጃዎች እና ግምገማዎች የተረጋገጡ አይደሉም የበለጠ ለመረዳት
ስለዚህ ኢ-መጽሐፍ
In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions. Establishing a baseline understanding of RSV sequence diversity prior to the widespread rollout of immunization will help to inform the development of new diagnostic and therapeutic products, facilitate assessment of the effectiveness of immunization programmes, better understand viral diversity and evolution, and assess the potential impact of RSV variants on the effectiveness of interventions. This document outlines a number of practical considerations regarding the scale and quality of sequencing. It also outlines the range of next generation sequencing (NGS) technologies suitable for RSV whole genome sequencing (WGS).
ለዚህ ኢ-መጽሐፍ ደረጃ ይስጡ
ምን እንደሚያስቡ ይንገሩን።
የንባብ መረጃ
ዘመናዊ ስልኮች እና ጡባዊዎች
የGoogle Play መጽሐፍት መተግበሪያውን ለAndroid እና iPad/iPhone ያውርዱ። ከእርስዎ መለያ ጋር በራስሰር ይመሳሰላል እና ባሉበት የትም ቦታ በመስመር ላይ እና ከመስመር ውጭ እንዲያነቡ ያስችልዎታል።
ላፕቶፖች እና ኮምፒውተሮች
የኮምፒውተርዎን ድር አሳሽ ተጠቅመው በGoogle Play ላይ የተገዙ ኦዲዮ መጽሐፍትን ማዳመጥ ይችላሉ።
ኢሪደሮች እና ሌሎች መሳሪያዎች
እንደ Kobo ኢ-አንባቢዎች ባሉ ኢ-ቀለም መሣሪያዎች ላይ ለማንበብ ፋይል አውርደው ወደ መሣሪያዎ ማስተላለፍ ይኖርብዎታል። ፋይሎቹን ወደሚደገፉ ኢ-አንባቢዎች ለማስተላለፍ ዝርዝር የእገዛ ማዕከል መመሪያዎቹን ይከተሉ።
